Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and safety of recombinant acellular pertussis-containing vaccines in healthy pregnant women
TCTR20180725004Phase 2Completed
- Sponsor
- BioNet
- Start
- Feb 2019
- Countries
- 1
01
Overview
Phase 2 trial in pertussis, sponsored by BioNet. Primary endpoints: Immunogenicity to pertussis antigens and Safety and tolerability. Started Feb 2019; status: completed.
02
Conditions
pertussis
Beyond the preview
Go deeper on TCTR20180725004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20180725004.